FDA Inspection
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company – FDA Inspection, May 5, 2023
Record Details
This FDA Inspection record concerns Bristol-Myers Squibb Company, with an inspection on May 5, 2023, issued by the New England District Office.
- Company
- Bristol-Myers Squibb Company
- Inspection Date
- May 5, 2023
- People
- Graeme E. Price
- Nirjal Bhattarai
- Viviana R. Ramirez (Issuing Officer)
- Zhongren Wu (FDA Associated Person)
View Company Profile
ID · 2b8d62b7-f73a-4fd8-bb70-69b6edafbbad
Inspection Facts
- Inspection number
- 1206159
- FDA center
- Biologics
- Outcome
- Form 483 issued
Other FDA inspections of Bristol-Myers Squibb Company
7| Date | Classification | Office | Project area |
|---|---|---|---|
| August 27, 2026 | Not classified | New England District Office | Human Cellular, Tissue, and Gene Therapies |
| July 8, 2025 | Not classified | New England District Office | |
| January 10, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 5, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 21, 2016 | Not classified | New England District Office |
Other documents for Bristol-Myers Squibb Company
- FDA Inspection 1338128 - 2026-08-27
- FDA Inspection 1272436 - 2025-07-08
- FDA Inspection 1115960 - 2020-01-10
- FDA Inspection 1008167 - 2017-04-05
- FDA Inspection 988152 - 2016-10-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.